GlassScriptPhysician profile
Hannah Vinyard
NPI 1184368896
$3,440.55
in general payments reported to CMS, 2019-2025
25 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $210 · 2023: $313 · 2024: $1,311 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $545.83 | 2022-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $511.14 | 2023-2025 | Dupixent |
| Ani Pharmaceuticals, INC. | $387.77 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $376.87 | 2023-2025 | |
| Genzyme Corporation | $236.64 | 2023-2025 | |
| Blueprint Medicines Corporation | $227.49 | 2024-2025 | Ayvakit |
| Amgen INC. | $185.55 | 2023-2025 | Tezspire |
| Pharming Healthcare, INC. | $132.12 | 2023-2025 | Ruconest |
| Csl Behring | $115.61 | 2022-2025 | Privigen, Hizentra |
| Genentech USA, INC. | $104.87 | 2024-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $98.07 | 2023-2025 | Takhzyro, Cuvitru |
| Ars Pharmaceuticals Operations, INC. | $97.59 | 2025 | Neffy |
| Organon LLC | $85.92 | 2025 | Vtama |
| Grifols USA, LLC | $66.19 | 2022-2024 | Xembify |
| Mylan Specialty L.P. | $45.74 | 2024 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39.32 | 2025 | Ebglyss |
| Alk-Abello, INC | $27.27 | 2025 | Neffy, Ragwitek, Odactra |
| Optinose US, INC. | $27.18 | 2025 | |
| Octapharma USA, INC. | $26.36 | 2025 | Octagam Immune Globulin (Human) |
| Hikma Pharmaceuticals USA | $21.22 | 2024 | Ryaltris |
| Galderma Laboratories, L.P. | $19.23 | 2025 | Nemluvio |
| Glaxosmithkline, LLC. | $16.79 | 2025 | Trelegy Ellipta |
| Phadia US INC. | $16.01 | 2024 | Immunocap |
| Tersera Therapeutics LLC | $15.77 | 2025 | Quzyttir |
| Abbvie INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Vinyard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.